Hence, tumor cell-extrinsic Axl expression could predict the therapy response in HCC patients, as they display infiltrated tumors of the “inflamed” subclass that respond to the currently used immune check point blockade. The gene discussed is AXL; the disease is hepatocellular carcinoma.